FIPB to take up 34 FDI proposals on Tuesday

The proposals include that of Ranbaxy Laboratories, Sistema Shyam and AT&T Global

Image
Press Trust of India New Delhi
Last Updated : May 11 2014 | 12:08 PM IST
The Foreign Investment Promotion Board (FIPB) will take up 34 FDI proposals, including that of Ranbaxy Laboratories, Sistema Shyam and AT&T Global, on Tuesday.

The other proposals which are before the board include those of Indian Rotocraft, Tech Mahindra, Bharti Shipyard and Johnson and Johnson Ltd.

The FIPB, chaired by Economic Affairs Secretary Arvind Mayaram, would meet on May 13 to decide on the proposals, sources said.

Also Read

Of the proposals before the FIPB, Sistema Shyam Teleservices has sought the government approval to raise foreign stake in the firm beyond the current 74%.

Russian conglomerate Sistema JSFC holds 56.68% in SSTL, Russian government 17.14% and 0.13% other foreign entities.

SSTL is the second operator after Vodafone that has approached FIPB for raising FDI limit.

Besides, American telecom firm AT&T Global Network, which provides internet bandwidth and related services to business houses, has approached FIPB to raise its stake in Indian arm. AT&T hold international and national long distance (ILD/NLD) telecom services licences in partnership with Mahindra Telecommunications.

Sources said that AT&T has plans to go solo in India as government has increased FDI cap in telecom sector to 100 per cent.

"Foreign ILD and NLD operators would be interested in raising their stake as joint ventures with Indian partners were mere regulatory formality," sources said.

Although it could not be immediately ascertained the proposal of Ranbaxy Laboratories, it may be recalled that last month Sun Pharma had announced to acquire Ranbaxy in an all stock transaction with a total equity value of $3.2 billion, along with debt of $800 million taking the overall deal value to $4 billion.

Currently, Daiichi owns around 63.41% of the shares of Ranbaxy. The company is scheduled to acquire about 9% stake in Sun Pharma as a result of the merger.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: May 11 2014 | 11:40 AM IST

Next Story